YTEN.Q Stock Overview
Operates as an agricultural bioscience company that focuses on commercializing products using the Camelina oilseeds in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Yield10 Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.31 |
| 52 Week High | US$17.26 |
| 52 Week Low | US$0.24 |
| Beta | 1.45 |
| 1 Month Change | -40.00% |
| 3 Month Change | -70.29% |
| 1 Year Change | -94.84% |
| 3 Year Change | -99.75% |
| 5 Year Change | -99.85% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M
Aug 10Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?
Nov 12
Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans
Jul 19Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 18Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation
Apr 14Yield10 Bio secures $12.7M capital raise
Feb 01Yield10 Bioscience under pressure on launching stock offering
Jan 29When Will Yield10 Bioscience, Inc. (NASDAQ:YTEN) Become Profitable?
Jan 22
Shareholder Returns
| YTEN.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.2% | -1.7% | -1.1% |
| 1Y | -94.8% | -5.0% | 22.4% |
Return vs Industry: YTEN.Q underperformed the US Biotechs industry which returned -5% over the past year.
Return vs Market: YTEN.Q underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| YTEN.Q volatility | |
|---|---|
| YTEN.Q Average Weekly Movement | 53.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: YTEN.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: YTEN.Q's weekly volatility has increased from 37% to 53% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 29 | Olly Peoples | www.yield10bio.com |
Yield10 Bioscience, Inc. operates as an agricultural bioscience company that focuses on commercializing products using the Camelina oilseeds in the United States. Its products include Camelina oil for production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA); and for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD), and sustainable aviation fuel (SAF). The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017.
Yield10 Bioscience, Inc. Fundamentals Summary
| YTEN.Q fundamental statistics | |
|---|---|
| Market cap | US$238.98k |
| Earnings (TTM) | -US$12.70m |
| Revenue (TTM) | US$750.00k |
0.3x
P/S Ratio0.0x
P/E RatioIs YTEN.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YTEN.Q income statement (TTM) | |
|---|---|
| Revenue | US$750.00k |
| Cost of Revenue | US$7.21m |
| Gross Profit | -US$6.46m |
| Other Expenses | US$6.25m |
| Earnings | -US$12.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -18.34 |
| Gross Margin | -860.93% |
| Net Profit Margin | -1,693.60% |
| Debt/Equity Ratio | -16.0% |
How did YTEN.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 22:23 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Yield10 Bioscience, Inc. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Han Jang | Aegis Capital Corporation |
| Jinming Liu | Ardour Capital Investments, LLC |
| Benjamin Klieve | B. Riley Wealth |